TY -的T1 -评价肺hypertension by right heart catheterisation – does timing matter? JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01892-2019 SP - 1901892 AU - Yogeswaran, Athiththan AU - Richter, Manuel Jonas AU - Sommer, Natascha AU - Ghofrani, Hossein Ardeschir AU - Seeger, Werner AU - Gall, Henning AU - Tello, Khodr Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/04/08/13993003.01892-2019.abstract N2 - Haemodynamic measurements from right heart catheterisation (RHC) are used for diagnosis and risk stratification in pulmonary hypertension (PH) [1]. The risk stratification scheme implemented in the guidelines for pulmonary arterial hypertension (PAH) has been validated in real-life cohorts [1–5]. However, the timing of measurements during RHC is not specified. We aimed to investigate the influence of the timing of measurements on RHC parameters and the consequences for risk stratification and diagnosis.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Yogeswaran reports non-financial support from University of Giessen, during the conduct of the study.Conflict of interest: Dr. Richter reports grants from German Research Foundation, non-financial support from University of Giessen, during the conduct of the study; grants from United Therapeutics, grants and personal fees from Bayer, personal fees from Actelion, personal fees from Mundipharma, personal fees from Roche, personal fees from OMT, outside the submitted work.Conflict of interest: Dr. Sommer reports personal fees from Actelion, outside the submitted work.Conflict of interest: Dr. Ghofrani reports grants from German Research Foundation, non-financial support from University of Giessen, during the conduct of the study; personal fees from Bayer, personal fees from Actelion, personal fees from Pfizer, personal fees from Merck, personal fees from GSK, grants and personal fees from Novartis, grants and personal fees from Bayer HealthCare, grants and personal fees from Encysive/Pfizer, grants from Aires, grants from German Research Foundation, grants from Excellence Cluster Cardiopulmonary Research, grants from German Ministry for Education and Research, personal fees from Takeda, outside the submitted work.Conflict of interest: Dr. Seeger reports grants from German Research Foundation, non-financial support from University of Giessen, during the conduct of the study; personal fees from Pfizer, personal fees from Bayer Pharma AG, outside the submitted work.Conflict of interest: Dr. Gall reports grants from German Research Foundation, non-financial support from University of Giessen, during the conduct of the study; personal fees from Actelion, personal fees from AstraZeneca, personal fees from Bayer, personal fees from BMS, personal fees from GSK, personal fees from Janssen-Cilag, personal fees from Lilly, personal fees from MSD, personal fees from Novartis, personal fees from OMT, personal fees from Pfizer, personal fees from United Therapeutics, outside the submitted work.Conflict of interest: Dr. Tello reports grants from German Research Foundation, non-financial support from University of Giessen, during the conduct of the study; personal fees from Actelion, personal fees from Bayer, outside the submitted work. ER -